<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - DURECT Corporation Announces Results From Phase 2a Clinical Psoriasis Trial
Image Overlay - DURECT Corporation Announces Results From Phase 2a Clinical Psoriasis Trial

DURECT Corporation Announces Results From Phase 2a Clinical Psoriasis Trial

January 15, 2020

DURECT Corporation Announces Results From Phase 2a Clinical Psoriasis Trial

DURECT’s psoriasis treatment, DUR-928, did not demonstrate a significant benefit over a placebo in trials, though it was well tolerated in the 22 patients tested. Based on these results, the company will stop development on DUR-928 and will instead focus on their alcoholic hepatitis treatment, which achieved positive results in its phase 2a trial. While not all clinical trials are successful, Yourway provides solutions and services to move a therapy all the way through to commercialization. 

 Back to Index
Media

Upcoming Events

GCSG 2024 US Conference

April 21-24, 2024
Naples, Florida

Precision in Clinical Trials Summit (Boston)

May 6-7, 2024
Hilton Boston Park Plaza

Media

Articles

Regulatory barriers in cross-border European pharmaceutical transport

Open chat
Come chat with us!
Hello! How can I help you?